Posted by Michael Wonder on 28 Aug 2016
CADTH recommends reimbursement of secukinumab (Cosentyx) for ankylosing spondylitis
23 August 2016 - CADTH publishes second outcome for Cosentyx this month.
The Canadian Drug Expert Committee has recommended that secukinumab be reimbursed for the treatment of adult patients with active ankylosing spondylitis (AS) who have responded inadequately to conventional therapy, if the annual drug plan cost for the treatment of AS with secukinumab should not exceed the annual drug plan cost of treating AS with the least costly biologic reimbursed.
